P

    PepGen Ltd (PEPG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.99
    -0.09 (-2.92%)

    Market Cap: $213.04M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(12/18)
    Avg Surprise
    -11.58%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.27
    Range$-0.29 - $-0.22
    6 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.28-6.9%
    60d ago$-0.27-2.0%
    30d ago$-0.28-3.1%
    7d ago$-0.28-3.1%
    Current$-0.27
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.20
    Range$-0.29 - $-0.15
    6 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.20---
    Sep 26EST
    		-$-0.27---
    Jun 26
    Reported Aug 6
    		$-0.26$-0.30+13.33%Beat+62.9%
    Mar 26
    Reported May 12
    		$-0.26$-0.35+26.01%Beat+72.1%
    Dec 25
    Reported Mar 4
    		$-0.27$-0.39+30.77%Beat+60.3%
    Sep 25
    Reported Nov 12
    		$-0.52$-0.56+7.14%Beat+21.2%
    Jun 25
    Reported Aug 7
    		$-0.70$-0.85+17.65%Beat+19.5%
    Mar 25
    Reported May 8
    		$-0.92$-0.75-22.67%Miss-46.0%
    Dec 24
    Reported Feb 24
    		$-0.68$-0.81+16.05%Beat+16.0%
    Sep 24
    Reported Nov 7
    		$-0.66$-0.77+14.29%Beat+32.7%
    Jun 24
    Reported Aug 8
    		$-0.87$-0.68-27.94%Miss-6.1%
    Mar 24
    Reported May 14
    		$-0.63$-0.64+1.56%Beat+8.7%
    Dec 23
    Reported Mar 6
    		$-0.81$-1.01+19.80%Beat-237.5%
    Sep 23
    Reported Nov 8
    		$-0.98$-0.80-22.50%Miss-24.1%
    Jun 23
    Reported Aug 8
    		$-0.82$-0.75-9.33%Miss+33.3%
    Mar 23
    Reported May 11
    		$-0.69$-0.74+6.76%Beat+96.4%
    Dec 22
    Reported Mar 23
    		$-0.24N/A+72.41%Beat+33.3%
    Sep 22
    Reported Nov 10
    		$-0.79$-1.00+21.00%Beat-46.3%
    Jun 22
    Reported Aug 12
    		$-1.23$-0.76-61.84%Miss-
    Mar 22
    Reported May 9
    		$-18.94$-4.61-310.85%Miss-
    Dec 21
    Reported Feb 11
    		$-0.36$0.00N/AMiss-
    Sep 21
    Reported Oct 1
    		$-0.54$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.29EV/EBITDA-3.12x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-75.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio13.36xQuick Ratio13.36x
    Trading Statistics
    Beta1.89Avg Volume1.05M
    52-Week High$7.8052-Week Low$1.17

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.11
    SMA 20$2.90
    SMA 50$2.35
    SMA 200$3.69
    EMA 10$3.06
    EMA 20$2.88
    EMA 50$2.52
    EMA 200$2.90

    MACD

    Line: 0.25Signal: 0.28Hist: -0.02

    ADX

    ADX: 50.1+DI: 30.1-DI: 12.6

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down12.0
    PSAR$3.56

    Bollinger Bands

    Upper Band$3.66
    Lower Band$2.15
    %B Position5194%(Upper)
    Band Width0.56

    RSI (14-Day)

    Neutral
    58.2

    Momentum Oscillators

    Stoch %K33.4
    Stoch %D49.2
    Williams %R-75.3
    ROC (10d)-1.6%
    Momentum-0.05
    CCI (20d)23.7
    MFI (14d)64.0

    Volatility Measures

    ATR (14d)$0.21(7.1%)
    StdDev (20d)0.38
    Hist Vol109.8%(High)

    Volume Flow

    VWAP$2.98
    OBV147.9M
    AD Line103.8M
    CMF (20d)0.347

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.3x(Low)
    VWMA (20d)$2.84

    Pivot Points

    R3$3.30
    R2$3.21
    R1$3.15
    Pivot Point$3.06
    S1$3.00
    S2$2.91
    S3$2.85

    Advanced Oscillators

    TSI33.53
    Ultimate Osc49.9
    KST505.79

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.49M$0$0$0$1.66M$0
    Cost of Revenue$0$0$1.06M$0$0$0$380,000$0$0$0$354,000$0
    Gross Profit$0$0$-1,058,000$0$0$0$-380,000$0$0$0$-354,000$0
    Operating Expenses$18.94M$18.94M$19.70M$18.65M$23.93M$31.32M$24.34M$23.17M$30.43M$19.80M$20.81M$24.78M
    R&D$12.52M$13.00M$13.85M$13.42M$18.39M$25.38M$18.96M$17.72M$25.06M$14.73M$16.30M$20.54M
    SG&A$6.42M$5.94M$5.85M$5.23M$5.54M$5.94M$5.38M$5.45M$5.36M$5.07M$4.51M$4.24M
    Operating Income$-18,939,000$-18,942,000$-19,705,000$-18,654,000$-23,932,000$-31,321,000$-24,345,000$-23,171,000$-30,425,000$-19,798,000$-20,811,000$-24,780,000
    Interest Income$1.09M$1.25M$1.42M$634,000$842,000$1.12M$1.46M$1.83M$2.12M$1.74M$1.35M$1.58M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-17,796,000$-17,748,000$-18,291,000$-18,026,000$-23,087,000$-30,202,000$-22,859,000$-21,384,000$-28,335,000$-18,020,000$-19,422,000$-23,290,000
    Income Tax Expense$16,000$15,000$0$0$0$0$0$0$0$0$0$0
    Net Income$-17,812,000$-17,763,000$-18,340,000$-18,026,000$-23,087,000$-30,202,000$-22,242,000$-21,384,000$-28,335,000$-18,020,000$-19,495,000$-23,290,000
    EBITDA$-18,591,000$-18,564,000$-20,649,000$-17,384,000$-23,112,000$-30,695,000$-26,927,000$-21,894,000$-27,561,000$-20,030,000$-20,756,000$-24,614,000
    EBIT$-18,889,000$-18,998,000$-19,710,000$-18,660,000$-23,929,000$-31,324,000$-24,319,000$-23,210,000$-30,456,000$-19,755,000$-20,768,000$-24,868,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PEPG

    News

    GSA Capital Partners LLP Makes New Investment in PepGen, Inc. $PEPG

    GSA Capital Partners LLP has initiated a new investment in PepGen, Inc. (NASDAQ:PEPG), acquiring 852,852 shares valued at approximately $1.535 million, representing a 1.23% stake. This investment comes as institutional ownership in PepGen collectively stands at 58.01%. The company recently reported better-than-expected quarterly EPS of -$0.26, and analysts maintain a "Moderate Buy" rating with an average price target of $11.50.

    MarketBeat•8/17/26•
    Bullish

    PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of "Moderate Buy" by Brokerages

    PepGen, Inc. (NASDAQ:PEPG) has received a "Moderate Buy" consensus rating from seven research firms, with an average 12-month price target of $11.50. Institutional investors hold 58.01% of the stock, with several funds increasing their positions recently. The company reported a quarterly loss of $0.26 per share, beating analyst estimates.

    MarketBeat•8/16/26•
    Bullish

    PepGen’s DM1 Bet Runs Into An FDA Hold And Dilution Fears

    PepGen (PEPG) is a clinical-stage biotech focused on its lead program PGN-EDODM1 for myotonic dystrophy type 1 (DM1). The company's stock performance is highly volatile and tied to clinical progress, regulatory outcomes, and financing events, including a recent FDA partial clinical hold and an at-the-market offering. Investors are awaiting key FREEDOM2 trial readouts in 2H 2026, which are critical for the company's valuation and future.

    Finimize•8/16/26•
    Somewhat-Bearish

    Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

    This article examines PepGen's cash burn rate and its implications for the company's future. It highlights the importance of monitoring cash burn for early-stage biotechnology companies like PepGen, especially given its significant clinical trial expenses. The analysis suggests that while the company has a substantial cash runway, investors should remain vigilant about its financial health.

    Moomoo•8/12/26•
    Somewhat-Bearish

    HC Wainwright Has Positive Outlook of PepGen FY2027 Earnings

    HC Wainwright has updated its financial outlook for PepGen, raising the FY2027 EPS estimate to a loss of $1.78 per share and maintaining a "Buy" rating. The firm also projects a $1.33-per-share loss for FY2029. PepGen currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $11.50, and recently reported quarterly EPS of $(0.26), beating consensus estimates.

    MarketBeat•8/11/26•
    Bullish

    Frequently Asked Questions About PEPG

    Does PEPG pay dividends?
    PepGen Ltd (PEPG) does not currently pay a regular dividend.
    What is PEPG's market cap?
    PepGen Ltd (PEPG) has a market capitalization of $213.04M with a current stock price of $2.99.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In